Fig. 4
Time to treatment discontinuation (a) and first hematologic (b) and nonhematologic (c) TEAEs by frailty group. TEAE Treatment-Emergent Adverse Event
Fig. 4 | Leukemia
Time to treatment discontinuation (a) and first hematologic (b) and nonhematologic (c) TEAEs by frailty group. TEAE Treatment-Emergent Adverse Event
